LNAIHealthcare · Biotechnology

LNAI Stock Forecast: Lunai Bioworks, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026

$1.12

+2.75% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 8 Oct 2026 — in the lower half.

Market cap

$5.1M

Ticker Nerd rank

34 / 100

Median analyst target

—

Analysts covering

—

Revenue$21K

Operating income−$1.4M

Net income−$2.6M

Free cash flow−$1.0M

Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown

Total return, dividends reinvested

−18.8%

−56.9%

YTD

−84.1%

−88.7%

From 52W high

−90.7%

From 52W low

+2.8%

$12

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

LNAI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lunai Bioworks, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026

34 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals

100

Size

Issuance

Volatility

Growth

Momentum

Revisions

Value

Quality

Accruals (100): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (9): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LNAI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LNAI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LNAI appears on the weeks it earns a place.

Performance

LNAI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Lunai Bioworks, Inc. returned −88.7% against +16.2% for the S&P 500, dividends included.

LNAI vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LNAI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Lunai Bioworks, Inc. (LNAI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.0×
Price / sales: 242.5×
Price / book: −0.4×
EV / EBITDA: −0.3×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: 100.0%
Operating margin: −6815.3%
Net margin: 0.0%

Returns & dividend

Return on equity: −325.5%
Return on assets: −9.6%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lunai Bioworks, Inc. (LNAI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Lunai Bioworks, Inc. has a market value of $5.1M and an enterprise value of $3.3M.
Revenue in the twelve months to 31 Mar 2026: $21K.
Net income over the same four quarters: −$128.3M, a −612568.1% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$5.3M.
Shares outstanding: 4.5M.
Trailing P/E: −0.0×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Lunai Bioworks, Inc. employs 29 people — $722.1 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

LNAI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
LNAILunai Bioworks, Inc.	$5.1M	34
LIMNLiminatus Pharma, Inc.	$5.0M	15
XBIOXenetic Biosciences, Inc.	$4.8M	29
CDIOCardio Diagnostics Holdings, Inc.	$5.5M	21
KALAKala Bio, Inc.	$5.5M	17
ENLVEnlivex Ltd.	$4.7M	11
PPCBPropanc Biopharma, Inc.	$4.6M	50

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lunai Bioworks, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LNAI news & analysis

Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement

PRNewsWire · 22 Sept 2026positive

Lunai Bioworks announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. to add human cellular phenotyping to its AI-driven Parkinson's disease discovery and validation platform. The agreement expands Lunai's Parkinson's workflow by connecting patient-derived subtypes with disease mechanisms, biomarkers, and therapeutic targets.

Why it matters — The exclusive agreement strengthens Lunai's Parkinson's platform by adding human cellular validation, expanding its discovery and validation capabilities in a key therapeutic area.

Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI

PRNewsWire · 16 Sept 2026positive

Lunai Bioworks, through its BioSymetrics subsidiary, shared results from a technical case study supporting the development of structure-based screening tools for chemical outputs generated by large language models and other AI systems. The study validated AChE screening with 5.1-fold enrichment using NIH Tox21 data, in the context of growing dual-use AI risks highlighted by OpenAI and Anthropic.

Why it matters — The demonstration of validated AI chemical-risk screening tools positions Lunai's BioSymetrics technology in the emerging area of managing dual-use safety risks associated with generative AI outputs.

Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint

PRNewsWire · 4 Sept 2026neutral

Lunai Bioworks (NASDAQ: LNAI) issued a correction to its press release regarding the second amended complaint, updating only a reference link. No other content in the original release was changed.

Why it matters — LNAI watchers would want to know that the reference link in the earlier release has been corrected, ensuring they have the accurate source for the second amended complaint details.

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

PRNewsWire · 27 Aug 2026negative

Lunai Bioworks (Nasdaq: LNAI) filed a Second Amended Complaint in its expanded naked short selling suit, naming six broker-dealers as defendants. The suit alleges securities fraud and market manipulation under Rule 10b-5, filed from Wilmington, Del. and Sacramento, Calif.

Why it matters — A LNAI watcher would follow this expanded litigation because it broadens the company's legal battle over alleged market manipulation in its shares.

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

PRNewsWire · 4 Aug 2026positive

Lunai Bioworks has signed a definitive collaboration agreement with BrainStorm Therapeutics, with initial Parkinson's disease data readout targeted for the first half of 2027. The executed Master Collaboration Agreement establishes an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and pharmaceutical partnering.

Why it matters — A LNAI watcher would care because the agreement establishes the company's integrated roadmap for its Parkinson's disease program and sets a target for initial clinical data readout in the first half of 2027.

FAQ

Frequently asked questions about LNAI stock

How does Ticker Nerd's model rank LNAI?

As at 8 Oct 2026, Lunai Bioworks, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (100 of 100).

What is the LNAI stock forecast for 2030?

No analyst covering Lunai Bioworks, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LNAI are extrapolating price history, which says nothing about the business.

How has LNAI stock performed over the past year?

Lunai Bioworks, Inc. returned -88.7% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lunai Bioworks, Inc. do?

Lunai Bioworks Inc. is a pre-clinical biotechnology company focused on developing medicines, diagnostics, and biodefense solutions.

What is the latest news on LNAI?

The most recent item we track (PRNewsWire, 22 Sept 2026): "Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement". Lunai Bioworks announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. to add human cellular phenotyping to its AI-driven Parkinson's disease discovery and validation platform. The agreement expands Lunai's Parkinson's workflow by connecting patient-derived subtypes with disease mechanisms, biomarkers, and therapeutic targets.

Company

About Lunai Bioworks, Inc.

Lunai Bioworks Inc. is a pre-clinical biotechnology company focused on developing medicines, diagnostics, and biodefense solutions. The company works across cancer, infectious disease, and precision medicine through genetically modified cell and immune-therapy platforms, including allogeneic dendritic cell vaccine programs for solid tumors such as pancreatic and breast cancers. Its business also includes AI-enabled diagnostics and multi-omics analytics designed to support early cancer detection and recurrence monitoring by identifying individual biomarkers, including in asymptomatic patients. Through its operating segments, Lunai Bioworks combines computational biology, experimental biology, and data-driven platforms to advance therapeutic discovery and improve clinical decision-making. The company is headquartered in Los Angeles, California, and serves healthcare-related markets in the United States and the Netherlands.

CEO Mr. David H. Weinstein · 29 employees · United States · https://www.lunaibioworks.com